Navigation Links
Islet Sciences Announces Receipt of $2.1 Million in Grant Support of Technology

NEW YORK, April 9, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, announced today that its wholly-owned subsidiary DiaKine Therapeutics, Inc. has received grant support totaling approximately $2.1 million. The grants include $1,831,250 from the National Institutes of Health (NIH) and $250,000 from the Iacocca Foundation.

"Clearly, the receipt of these grants will help our company execute our ongoing initiatives and is a vote of confidence from such well known organizations," said Dr. Jerry L. Nadler, Islet Sciences Director. "As we continue to make progress with our diabetes therapies this grant support is a testament to the value of our therapies which represents such a large market opportunity for Islet Sciences."

"We are pleased to announce these grants which obviously strengthens our value proposition," said John Steel, Chairman and CEO of Islet Sciences. "Our approach to the treatment of diabetes in addition to other inflammatory diseases and autoimmune disorders are what attracted these esteemed institutions as we capitalize on the growing opportunities in this field. We look forward to announcing additional milestones in the coming months."

About Islet Sciences, Inc.

Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes.  The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties.   Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors.  Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission.  The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.

Investor Contact:
Jeff Ramson
ProActive Capital Resources Group
(646) 863 6893


SOURCE Islet Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
2. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
3. Beta-Pro Donates Human Islet Cells to Diabetes Researcher
4. Pigs to Be Genotyped to Improve Selection and Breeding for Pancreatic Islet Cell Research
5. BioLife Solutions HypoThermosol(R) Adopted by MicroIslet for Processing Pancreatic Islet Cells to Treat Diabetes
6. Human Pheromone Sciences Voluntarily Files With SEC for Termination of Registration
7. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
8. Frost & Sullivan Announces Cutting Edge Life Sciences Research on the Horizon
9. Nautilus Neurosciences, Inc. Announces a New Approval for CAMBIA® for the Acute Treatment of Migraine
10. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
11. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
Post Your Comments:
(Date:12/1/2015)... ROSEVILLE, Minn. , Dec. 1, 2015  The ... the recipient of the 2015 Tekne Award in the ... th at the Minneapolis ... who have played a significant role in developing new ... people living around the world. Clostridium difficile ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... specializing in scientifically backed, age-defying products, is featured as the cover story ... exponential success and unrivaled opportunities that Nerium provides. Success from Home magazine ...
(Date:12/1/2015)... ... December 01, 2015 , ... Matthew “Tex” VerMilyea, PhD, HCLD, has joined Texas ... oversee all IVF lab procedures as well as continue his research efforts into the ... miles to Auckland, New Zealand to bring home a High Complexity Clinical Laboratory Director ...
(Date:11/30/2015)... ... ... announced the opening of a new core patient care hub with the opening of ... are part of GSCG’s expansion efforts in Latin America. , Both the Arica and ... from around the world. , The clinics will be headed by Victor Perez, M.D. and ...
Breaking Biology Technology:
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
(Date:10/26/2015)... 26, 2015 ... adds Biometrics Market Shares, Strategies ... well as Emerging Biometrics Technologies: Global ... its collection of IT and Telecommunications ... --> . ...
Breaking Biology News(10 mins):